Could an immune treatment ease severe OCD in kids with PANS?

NCT ID NCT04508530

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a medicine called Panzyga (given through a vein) can reduce obsessive-compulsive symptoms in children aged 6 to 17 with a condition called PANS or PANDAS. These children experience a sudden, severe onset of OCD and other neuropsychiatric problems. The study compared Panzyga to a placebo over 9 weeks, measuring changes in OCD severity using a standard rating scale. The goal was to see if Panzyga could provide meaningful symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Octapharma Research Site

    Tucson, Arizona, 85712, United States

  • Octapharma Research Site

    Little Rock, Arkansas, 72202, United States

  • Octapharma Research Site

    Los Angeles, California, 90024, United States

  • Octapharma Research Site

    Palo Alto, California, 94305, United States

  • Octapharma Research Site

    Centennial, Colorado, 80112, United States

  • Octapharma Research Site

    Boston, Massachusetts, 02114, United States

  • Octapharma Research Site

    Lebanon, New Hampshire, 03756, United States

  • Octapharma Research Site

    Genova, 16147, Italy

  • Octapharma Research Site

    Roma, 00161, Italy

  • Octapharma Research Site

    Roma, 00186, Italy

  • Octapharma Research Site

    Gothenburg, 41685, Sweden

  • Octapharma Research Site

    Stockholm, 17164, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.